According to The Insight Partners' research, the South & Central America Prescription Drugs Market was valued at US$ 52.5 Billion in 2024 and is expected to reach US$ 82.5 Billion by 2031, registering a CAGR of 6.7% from 2025 to 2031.
Growth of personalized and precision medicine and development and adoption of innovative and specialty drugs are among the critical factors attributed to driving the South & Central America prescription drugs market growth.
Personalized and precision medicine is experiencing growing technological advancements, increasing understanding of genomics, and rising adoption of personalized therapeutic approaches. Personalized medicine involves customizing healthcare based on individual genetic, environmental, and lifestyle factors, allowing for more effective and targeted treatments. The development of targeted cancer therapies such as trastuzumab (Herceptin) for HER2-positive breast cancer exemplifies how genetic profiling can identify patients who will benefit most from specific treatments, improving efficacy and reducing adverse effects. The increasing adoption of companion diagnostics is expected to integrate genetic testing into routine clinical practice, enhancing drug efficacy and safety. Technological advancements such as artificial intelligence (AI) and big data analytics are accelerating discoveries in personalized medicine. AI-driven algorithms analyze vast datasets to predict individual responses to drugs, identify new therapeutic targets, and streamline drug development processes. In January 2024, Brazilian firm Bioma4me joined forces with SOPHiA GENETICS to strengthen its genetic testing capabilities for precision medicine. This partnership allows Bioma4me to leverage SOPHiA DDM technology to perform easier genetic analysis for rare diseases as well as identify and prescribe personalized therapy approaches to the Brazilian populace. Bioma4me is focused on bringing affordable, rapid, and accurate genetic testing, creating a new era in the healthcare landscape of Brazil. This initiative demonstrates the ongoing movement toward personalized medicine within South America. Therefore, technological innovations and increasing clinical adoption of more effective, safer, and patient-centric therapies, transforming healthcare delivery and outcomes globally, are expected to contribute to the market growth in the coming years.
On the contrary, high drug prices and affordability issues hamper the growth of the South & Central America prescription drugs market.
South & Central America Prescription Drugs Market Segmentation Analysis:
- By Product Type, the South & Central America Prescription Drugs Market is segmented into Branded and Generics. The Branded segment is projected to expand at 6.3% CAGR during 2025 - 2031.
- By Drug Type, the South & Central America Prescription Drugs Market is segmented into Small Molecule and Biologics and Biosimilars. The Small Molecule segment is projected to expand at 3.9% CAGR during 2025 - 2031.
- By Therapeutic Area, the South & Central America Prescription Drugs Market is segmented into Oncology, Cardiovascular Diseases, Neurological Diseases, Metabolic Diseases, Respiratory Diseases, Immunology, and Others. The Oncology segment is projected to expand at 7.4% CAGR during 2025 - 2031.
- By Route of Administration, the South & Central America Prescription Drugs Market is segmented into Oral, Injectable, Topical, and Others. The Oral segment is projected to expand at 7.0% CAGR during 2025 - 2031.
- By Distribution Channel, the South & Central America Prescription Drugs Market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment is projected to expand at 7.3% CAGR during 2025 - 2031.
By country, the South & Central America Prescription Drugs Market is categorized into Brazil, Argentina, Rest of South & Central America. Brazil is projected to expand at 7.3% CAGR during 2025 - 2031.
Key players operating in the Prescription Drugs Market are GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Sanofi SA, Johnson & Johnson, AstraZeneca Plc, AbbVie Inc, Eli Lilly and Co, ESTEVE, among others.
- In September 2023, Sandoz, a global leader in generic and biosimilar medicines, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), had adopted a positive opinion recommending marketing authorization for their biosimilar trastuzumab (150 mg, for intravenous use), developed by EirGenix, Inc.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com